Alexander (Sasha) Kagansky is a Visiting Fellow at the University of Stirling, and is setting up an international consortium Biodiversity-to-Biomedicine (Bio2bio). He is also leading the Centre for Genomic and Regenerative Medicine, School of Biomedicine of the Far Eastern Federal University (Vladivostok, UK). Apart from the research in the lab, he is leading the international PhD course for the entrepreneurship in biotechnology, and regularly organizes public engagement of science activities for different target groups including school students, and general public – in different parts of the world, resulting in new collaborations between scientists and artists. He is also a member of the executive committee of the Global Young Academy, member of the Young Academy of Scotland, and Mason Institute for Medicine, Life Sciences and the Law, and Innogen institute.
His academic qualifications include PhD (2004), Molecular Biology, National Institutes of Health, Bethesda, USA and Cytology Institute, Saint-Petersburg, Russia; MSc (1998) and BSc (1996) in Biophysics from Saint-Petersburg Polytechnical University, Russia.
Despite technological and cultural advances there are no truly effective drug treatments for the major lethal diseases, such as cancer. In addition, drug resistance to existing infections, cancer, is increasing. Therefore is imperative need to develop new treatments. The complexity of cellular pathways in various tissues is such that the highest promise in the field is expected from phenotype-based screening of chemically diverse compounds and their combinations via state-of-the-art multi-parametric analysis. On the other hand we are loosing biodiversity at the unprecedented rate, which also results in loosing known and novel medicinal species. That is why in GYA we have started an ambitious and timely international initiative: to re-visit natural compounds under investigation within remaining regions with high biodiversity (such as Mauritius, Philippines, Russia, etc.) and investigate them in high capacity cell-based and in vitro assays under development in the world’s top cancer research centers (e.g. in the University o Edinburgh). We anticipate that this project will unite the world for solving the outmost problems of our times.